Introduction
a-fetoprotein (AFP), a major human serum protein in fetal life, was first detected in 1956 [1] . It is produced by the yolk sac, the fetal liver and, in small amounts, by the gut [2] . The serum concentration of AFP increases rapidly after the fourth week of gestation and reaches peak levels of 1.2 to 4.0 mg/ml at the age of 12 to 16 weeks' gestation [3, 4] . This concentration, more than one million fold higher than the average adult serum values, then decreases by 34 weeks' gestation to less than 2% of the maximum at delivery. AFP levels fall below 15 ug/ml by 8 to 12 months of age [2, 5] . Normal adult levels stay at approximately 2 to 4 ug/ml [6] .
AFP is a single chain glycoprotein with a molecular weight of approximatly 70,000 kD. The AFP gene together with the genes for albumin, vitamin D-binding protein and a-albumin constitute the albumin multigene family. The members of this family are tandemly linked in the 4q subcentromeric region of the same DNAstrand and map to the locus 4qll-4ql3 [7] . In 1983 the complete nucleotide sequences of human AFP mRNA and cDNA were published [8] . In 1997 human recombinant AFP-cDNA was successfully cloned in E. coli [9] .
The control mechanism of expression of human AFP remains poorly understood. Several enhancer, promotor and transcription control elements as well as regulating nuclear receptors and interacting growth factors have been identified. A sequence analysis in the five-prime flanking region of the AFP gene obtained from a family with hereditary persistence of AFP revealed a mutation in a potential enhancer element site (G-to-A transition at position -199 in hepatocyte nuclear factor I binding site) [10] .
The physiological functions of AFP are not well known. Regulation of the osmotic pressure, carrier transport functions and immunmodulatory effects involved in the protection of the conceptus from potentially harmful maternal anti-fetal reactivity as well as in the establishment of T-helper cell tolerance are suspected [11, 12] . Further, APF may regulate cell proliferation and differentiation synergistically with other growth factors [9, [13] [14] [15] . Recently, AFP has been shown to induce apoptosis in human hepatoma cell cultures [16] .
The role of AFP as a tumor marker for hepatoblastoma, hepatocellular carcinoma and germ cell tumors is well established. Moreover, AFP determination is used as a screening test in pregnancy. AFP is also found to be elevated in both, children and adults in several diseases and conditions which will be discussed. The following report discusses a case of inherited elevation of a-fetoprotein. The existence of this condition needs to be considered in patients with an elevated a-fetoprotein without a clear explanation. Table 1 . AFP values of the individual family members (cf. Figure 1 In February 1996 a 39-year-old white man with an unremarkable medical history but who was concerned that he might have testicular cancer presented at our outpatient unit. He had felt a small nodule in his left testicle. By our examination, the left testicle was slightly increased in size. At the lower pole a nodule of 3 mm in diameter was present. The remaining physical examination was normal. An ultrasound of the testicle confirmed a fibrotic like nodule in the tunica albuginea near the lower testicular pole and also showed that the neighbouring testicular parenchyma was of increased density. His serum AFP level was elevated (24 ug/ml; normal < 10 ug/ml by RIA). b-HCG, LDH, liver-and kidney function tests were normal. Surgical exploration with open biopsy was carried out. Histology showed scar tissue in the tunica albuginea and testicular parenchyma with intact spermiogenesis and no tumor tissue. His postoperative AFP level remained elevated at 20 ug/ml. An abdominal CT-scan and chest X-ray showed no abnormality. Laboratory tests were normal for hepatitis A, B and C. We decided to screen family members of the proband thinking of an hereditary trait. AFP was found to be elevated in five out of 13 relatives within three generations. The levels ranged from 20 to 51 ug/ml. The pedigree is consistent with an autosomal dominant inheritance pattern (Table 1 and Figure 1 ).
Discussion

Hereditary persistence ofy.-fetoprotein
A literature search was done using Ovid-Medline by key word 'oc-fetoprotein (genetics)' as well as V. A.
McKusick's catalog of human genes and genetic disorders [17] . Hereditary persistence of oc-fetoprotein (HPAFP) was first described in a Scottish family by FergusonSmith in 1983 [18, 19] . A 38-year-old pregnant woman, tested as part of a routine maternal screening program for neural tube defects, was found to have 'grossly' elevated AFP levels. The AFP level in the amniotic fluid was normal and a healthy child was born. The mother's AFP elevation persisted after delivery. The infant and two out of three siblings also had elevated serum AFP. Subsequently, 72 family members were tested and 22, [20, 21] . A second family was reported in a letter by Staples in 1986 in a patient with hereditary spherocytosis and unexplained persistent elevation of AFP after radical right orchiectomy for testicular seminoma [22] . The preoperative AFP value was 21 kU/1 (normal < 5 kU/1 by RIA). Postoperative serum AFP levels remained elevated but stable at 14-21 kU/1. A family study revealed another five family members within two generations with elevated APF unrelated to any disease.
The third report described a 42-year-old man with a history of recurrent cramping suprapubic and back pain one year after removing a benign left testicular cyst [23, 24] . AFP was found to be elevated. Careful evaluation for occult testicular cancer and hepatic disorders revealed no abnormality. The repeated AFP levels remained in the range of 30 to 36 ug/ml (normal < 10 ug/ml). A family study revealed elevated AFP levels in three out of nine family members within two generations. The APF levels for each family member remained fairly stable throughout repeat testing over six months. The highest levels were found in the brother's serum (52-64 ug/ml).
The fourth report of HPAFP deals with a Chinese family [25] . The AFP levels in the proband ranged form 21 to 129 ug/ml with a median level of 90 ug/ml. Two other family members, the father and the brother, had also AFP elevations in the range of 46 to 198.2 ug/ml. The relatively high values and the wide range of the levels in this family are remarkable.
Pregnancy
Serum AFP can rise above normal in distinct conditions and several diseases. The clinical uses of AFP determination are shown in Table 2 . During pregnancy AFP levels in the maternal serum physiologically increase in the second trimester due to raising fetal production and release of this protein through the placental barrier. The median level (50 percentile) between 16 and 20 weeks' gestation rises from 30 to 75 ug/ml [26] . AFP levels in the maternal blood elevated above those normaly seen are suspicious for open fetal neural tube defects (NTD), i.e., anencephaly or open spina bifida [26] [27] [28] . High levels are also associated with increased risk for other adverse gestational outcomes such as other major congenital defects, fetal death, low birth weight, newborn complications, oligohydramnion, abruptio placentae and preeclampsia [29, 30] . In current clinical practice the screening test for AFP is offered to all pregnant women between 16 to 20 weeks' gestation. AFP levels are elevated in approximatly 5% to 10% of all pregnancies. Cut-off values of >2.0 to 2.5 multiples of the median (MoM) deserve further exploration by ultrasound and amniocentesis. False positive elevated AFP is most frequently due to incorrect assertion of gestational age. HPAFP has to be taken into account.
Determination of lower than normal maternal serum AFP in pregnancy is also widely used as a screening test for Down's syndrome. In women carrying a Down's syndrome fetus the median AFP level is less than 0.8 MOM [31] . The best time for screening is between 15 and 20 weeks of gestation. By this time, approximately 25% to 35% of Down's syndrome fetuses will be detected. Enhanced detection rates of 60% with a similar false positive rate < 5% can be achieved by performing triple marker screening including AFP, HCG and unconjugated estriol (uE3) [32] . A false normal AFP which can be measured in pregnant woman with HPAFP could misslead the physician.
Congenital nephrosis is a rare inherited autosomal recessive disease mainly found in Finland which causes massive proteinuria and therefore markedly increases AFP in the amniotic fluid and in the maternal serum. Renal transplantation in early neonatal life is the only effective treatment. Screening for the disease using measurement of AFP has been shown to be highly effective [33, 34] . An AFP level in the maternal serum > 2.5 MoM leads to amniocentesis and in case of confirmation to possible termination.
Childhood
Elevated AFP levels in childhood are known to be present in several diseases such as hereditary tyrosinaemia, ataxia teleangiectasia, hepatoblastoma, hepatocellular carcinoma, malignant germ cell tumors of testicular/ovarian origin, intracranial germ cell tumors and cystic fibrosis [35] [36] [37] . The clinical situations in which AFP determination is currently used are listed in Table 2 .
Hereditary tyrosinaemia is an autosomal recessive inborn error of metabolism, caused by deficiency of fumarylacetoacetase, an enzyme most abundantly present in the liver and kidneys [38] . The disease is characterized by aggressive and fatal hepatic failure or, more protracted, liver cirrhosis with porphyric crises, renal tubulopathy and finally hepatoma in early infancy [39] . AFP levels are highly elevated (> 5000 ng/ml), thus, hampering its use as a marker for detection of primary liver cancer in this disease [40] .
Markedly elevated levels of AFP (44-2800 ug/ml) have uniformly been detected in patients with ataxia teleangiectasia, an autosomal recessive multisystem disorder characterized by cerebellar ataxia, oculocutaneous teleangiectasia and occasionally abnormal liver function and recurrent infections [41] . The latter is caused by a disease related immunodeficiency affecting both the humoral and cellular immune system. Pathogenetically, a defective interaction between two major germ lines, the entoderm and the mesoderm occurs. As a consequence, normal tissue development and maturation fails in lymphoid tissue and gut-associated organs. Hepatoblastoma is a rare malignant disease, usually affecting children in the first three years of life and associated with extremly high AFP levels between 100 and 1000 ug/ml. However, AFP levels below 100 ug/ml have been reported. Despite modern multimodality treatment the prognosis is grave. Demonstrating falling AFP levels in the early phases of treatment phase is the strongest indicator of survival, whereas the initial AFP level seems to be a weak prognostic marker [42] . The AFP elevation in these three mentioned clinical situations in childhood should be easily distinguishable form HPAFP since the marker levels are generally very high and the associated symptoms preclude a benign trait.
Adults
In adults the most impressive AFP levels are seen in patients with hepatocellular carcinoma and non-seminomatous germ cell tumors [43] . AFP has also been found to be elevated in several other neoplastic diseases such as pancreatic cancer (23%), gastric cancer (20%), colorectal cancer (5%), bronchial cancer (7%) and rarely cancer of the esophagus, small bowel, gallbladder, breast, endometrium, kidney, prostate and metastatic liver dis-ease [44] . In addition several non-neoplastic liver diseases are associated with transient or permanent elevation of AFP. This includes acute viral hepatitis (^52%), chronic hepatitis (^58%) liver cirrhosis of different origines (<47%), alcoholic or drug induced liver damage, liver trauma and acute liver necrosis (Table 2) [45, 46] . The AFP levels in patients with non-neoplastic liver diseases rarely exceed 500 ug/ml [47] [48] [49] .
Hepatocellular carcinoma (HCC) constitutes one of the most common cancers in the world with an annual incidence of approximately 1 million patients [50] . Patients with cirrhosis are at greater risk for developing HCC with a yearly incidence between 3% to 11% [51] . In this group, elevated or rapidly increasing AFP levels are predictive for the development of HCC. However, about half of patients with cirrhosis followed in screening programs who later develop HCC have consistently normal or fluctuating AFP levels [52] [53] [54] . Despite this, AFP assay combined with liver ultrasound and fine needle biopsy of suspicious lesions is widely accepted as the screening tool of choice [55, 56] . Postsurgical serum AFP values persisting above 20 ug/ml are highly predictive for early relapse (80% within one year) and an increase of AFP in the follow up is almost always a sign of recurrence within months [57] . The use of radiolabeled polyclonal and monoclonal anti-AFP antibodies has improved the sensitivity of AFP tests for detection of small HCC and occult metastatic disease [58] . Anti-AFP antibodies are also under study for radioimmunotherapy [59] .
In non-seminomatous germ cell tumors (NSGCT) the role of AFP, HCG and LDH as tumor markers is well established in diagnosis, staging, monitoring therapy, follow up and prognosis [60, 61] . AFP is produced in approximatly two third of the patients with GCT containing yolk sac elements (embryonal carcinomas, teratocarcinomas, teratomas and endodermal sinus tumors). Ninety percent of patients with NSGCT at any stage of the disease have elevated serum levels for AFP, HCG or both before treatment. AFP levels above 10,000 ug/ml are known to be a poor prognostic factor with a five-year survival of 48% [62] . During therapy, AFP and HCG should decline to normal according to their halflife of three to six days and 18 to 36 hours respectively, indicating an effective treatment [63, 64] . If the markers remain above normal, occult or overt residual disease is highly probable. Rising markers after successful treatment usually predict recurrent disease.
The tumor markers HCG and AFP in patients with germ cell tumors can be falsly positive initially or after successful treatment. A falsly positive HCG may indicate elevated luteinizing hormone due to iatrogenic hypogonadism secondary to bilateral orchiectomy, oophorectomy or chemotherapy. With testosterone administration the assay usually converts to negative [65] . AFP can be false positive after intensive chemotherapy due to drug induced liver dysfunction [66] [67] [68] . The AFP binding ratio to concanavalin-A, a lectin, is highly sensitive and specific and is able to distinguish between AFP derived form germ cell tumor tissue and AFP derived from damaged liver cells [69, 70] . Another lectin binding test, which is more labor intensive, can separate AFP produced by liver cancer cells from AFP of non-neoplastic liver disease or germ cell tumor origin [71, 72] .
Conclusion
Our report describes the fifth family with hereditary persistence of elevated AFP. With regard to the autosomal dominant trait, the occurrence of this clinically entirely benign disorder may be underestimated. To avoid inappropriate treatment decisions, this genetic condition should be considered in children and in adults with unexplained and persistent elevation of AFP, e.g., those screened for hepatocellular carcinoma or diagnosed for germ cell tumor. It should also be recognized in AFPscreening for neural tube defects and Down's syndrome during pregnancy. Hereditary persistence of a-fetoprotein can be easily confirmed by analyzing AFP levels in family members.
